Citrate Molarity Shapes mRNA-LNP Function

Lipid nanoparticles are widely used to protect and deliver messenger RNA, but their performance depends on more than lipid identity and average particle size. The reference study, The influence of citrate buffer molarity on mRNA-LNPs: Exploring factors beyond general critical quality attributes, examines how the concentration of citrate in the aqueous phase affects firefly luciferase mRNA-LNPs. Its central contribution is practical: formulations that look similar under standard physicochemical tests can still differ in cellular uptake, transfection, and animal-level expression.

Study Background and Research Question

mRNA-LNP manufacturing commonly combines an organic phase containing lipids with an aqueous phase containing RNA and buffer. Rapid mixing promotes nanoparticle formation as the solvent environments change. The resulting particles are usually evaluated through critical quality attributes such as hydrodynamic size, polydispersity index, zeta potential, and nucleic acid encapsulation efficiency. These measurements are important for batch characterization, but they do not necessarily capture every structural feature that controls biological activity.

Citrate buffer is frequently used to dissolve mRNA during LNP preparation. Its molarity may influence ionic strength, RNA–lipid interactions, local assembly kinetics, and the organization of lipids during nanoparticle formation. The research question was therefore whether changing citrate concentration would affect the physical and functional properties of mRNA-LNPs, even when conventional quality attributes remained within broadly acceptable ranges.

The investigators used LNPs containing SM-102, an ionizable lipid associated with clinically relevant mRNA-LNP systems, and firefly luciferase mRNA as a quantifiable reporter cargo. This reporter enables functional comparisons because luciferase expression can be measured through substrate-dependent bioluminescence in cultured cells and in animal models. The design separates the effect of the aqueous buffer variable from the broader question of which reporter sequence is used.

Key Innovation from the Reference Study

The study’s innovation lies in connecting a manufacturing input that is often treated as secondary—citrate molarity—with biological performance. Rather than assuming that similar mean size, low PDI, and high encapsulation imply equivalent products, the authors evaluated size distributions, morphology, cellular internalization, in vitro transfection, and in vivo expression.

This is an important shift in how LNP quality can be interpreted. Average diameter is a summary value, whereas a formulation may contain subpopulations with different sizes or shapes. Those subpopulations can influence protein corona formation, cell association, endosomal trafficking, and payload release. The study does not establish a single universal mechanism for the observed effects, but it provides evidence that subtle changes in lipid packing or particle organization may be functionally meaningful.

For researchers developing mRNA delivery systems, the message is not that citrate is intrinsically unsuitable. Instead, the data indicate that citrate concentration should be defined, controlled, and justified as part of the formulation and process design space. Buffer molarity may be especially relevant when transferring a formulation between laboratories, scales, mixing platforms, or RNA concentrations.

Methods and Experimental Design Insights

The experimental comparison used citrate buffers at 50 mM, 100 mM, and 300 mM to prepare SM-102 LNPs containing firefly luciferase mRNA, as reported in the reference study. This three-level design allowed the investigators to compare commonly moderate citrate conditions with a substantially higher molarity while retaining the lipid composition and reporter cargo as controlled elements.

Particle characterization included average size metrics, including z-average and mode, together with PDI and encapsulation efficiency. The study also examined distributional measures such as D10, D50, and D90 and assessed particle morphology. These complementary measurements are valuable because a similar average diameter does not prove that two preparations have the same size distribution or internal organization.

Functional testing proceeded beyond physicochemical characterization. Cellular internalization was measured to determine whether particles entered cells similarly across buffer conditions. In vitro transfection was then used to assess reporter expression, providing a functional readout of the complete delivery pathway rather than uptake alone. Finally, the formulations were evaluated in mice, allowing the authors to test whether the in vitro pattern translated into differences in whole-animal luciferase expression.

Protocol Parameters

• Citrate comparison: Prepare the aqueous mRNA phase using 50 mM, 100 mM, or 300 mM citrate when reproducing the reference comparison; these values are study parameters reported in the reference paper.
• Controlled formulation elements: Retain the SM-102-based lipid composition and firefly luciferase mRNA cargo when the goal is to isolate the effect of citrate molarity rather than compare different LNP chemistries.
• Characterization sequence: Measure average size, PDI, encapsulation efficiency, size subpopulations, and morphology before interpreting biological results; this is a workflow recommendation informed by the study design.
• Functional endpoints: Pair cellular internalization with in vitro reporter expression because uptake and productive cytosolic delivery are related but distinct events.
• In vivo confirmation: Use animal expression studies only after establishing a controlled formulation comparison and a prespecified luciferase readout; the reference study supports the value of this confirmation but does not provide a universal dosing protocol.

The design also illustrates why process parameters should be documented with the same care as lipid ratios. Mixing ratio, flow conditions, RNA concentration, buffer concentration, pH, and post-preparation handling can interact. A buffer comparison is therefore most informative when other parameters are held constant and when replicate batches are tested.

Core Findings and Why They Matter

At the level of average particle size, citrate molarity did not produce a statistically significant difference when the formulations were compared using z-average or mode. All three groups also showed low PDI and high encapsulation efficiency, according to the published findings. If evaluation had stopped at these measurements, the formulations might have been judged broadly equivalent.

More detailed analysis suggested a different interpretation. Differences in D10, D50, and D90 values, together with morphology observations, indicated that citrate concentration may influence lipid packing or the distribution of particle subpopulations. The reported differences were subtle, so they should not be treated as proof of a single structural mechanism. Nevertheless, they show why distributional and morphological analyses can add information that a single mean diameter cannot provide.

The most consequential result was functional. The formulation made with 300 mM citrate showed reduced cellular internalization and lower in vitro transfection efficiency compared with the lower-molarity conditions. This finding is especially relevant for mRNA-LNP development because high encapsulation does not guarantee that the encapsulated RNA will reach the cytosol or be translated efficiently.

The in vivo results followed the same general pattern. Mice receiving the 50 mM and 100 mM formulations showed similar luciferase expression, whereas the 300 mM formulation produced lower expression, as described in the reference study. The animal data strengthen the practical interpretation of the cell experiments, while still leaving open which biological step—particle distribution, cell association, endosomal escape, RNA release, or another process—accounts for the reduced output.

These observations matter for analytical strategy. A formulation can meet broad specifications for size, PDI, and encapsulation while failing to match a comparator in uptake or potency. For this reason, LNP development should use a tiered characterization plan: routine CQAs for batch consistency, higher-resolution structural measurements for formulation insight, and cell-based or in vivo assays for biological confirmation.

Comparison with Existing Internal Articles

The internal article Advancing Translational Research with EZ Cap™ Firefly Luciferase mRNA approaches the subject from the perspective of reporter selection and translational workflow design. It emphasizes how a luciferase mRNA readout can support quantitative studies of expression and delivery. The reference paper complements that perspective by showing that the reporter signal is also sensitive to upstream formulation decisions, including the molarity of the aqueous citrate buffer.

The two resources should therefore be read as addressing different layers of the same experimental system. A well-designed reporter assay can provide a sensitive endpoint, but it cannot compensate for uncontrolled LNP preparation variables. Conversely, careful buffer control is more informative when the assay has a reproducible and quantitative expression readout. The reference study adds a formulation-quality dimension to the internal article’s focus on translational measurement.

Limitations and Transferability

The results should be interpreted within the boundaries of the experimental system. The comparison used one ionizable-lipid platform, SM-102, one mRNA reporter, and the tested citrate conditions. Other ionizable lipids, helper lipids, PEG-lipids, RNA sequences, RNA concentrations, mixing systems, or storage conditions may respond differently. The findings support investigating citrate molarity; they do not define a universal optimum for all mRNA-LNP products.

The study also identifies, rather than fully resolves, the mechanism behind the lower performance at 300 mM citrate. Morphology and size-subpopulation data suggest altered assembly or lipid packing, but those observations do not by themselves establish how the particles behave during serum exposure, cellular uptake, endosomal trafficking, or intracellular RNA release. Additional orthogonal assays would be needed to assign causality to a particular step.

Transferability to a new laboratory should therefore rely on comparability testing rather than assumption. Researchers should reproduce the relevant buffer concentration, mixing conditions, lipid-to-RNA relationship, and analytical methods before drawing conclusions. Functional testing is particularly important when a formulation is scaled, moved to another mixer, or combined with a different capped mRNA. The paper’s broader lesson is that apparently minor process changes can become meaningful when they alter particle heterogeneity or biological interactions.

Research Support Resources

Researchers can use EZ Cap™ Firefly Luciferase mRNA (SKU R1018) to support similar workflows, including an mRNA delivery and translation efficiency assay, a gene regulation reporter assay, or in vivo bioluminescence imaging. The product is a Cap1-capped firefly luciferase transcript with an optimized poly(A) tail; it can serve as a Firefly Luciferase mRNA with Cap 1 structure and as a bioluminescent reporter for molecular biology. Researchers should follow the product information for RNase-controlled handling, aliquoting, storage, and compatibility with the selected transfection workflow. The reference study indicates that reporter choice should be paired with explicit control of buffer molarity and broader LNP process parameters.